E. A. de Bruijn
Impact in
- Toxicology top 1%
- Oncology top 2%
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
Papers in
-
- Cancer therapeutics and mechanisms 21
- Angiogenesis and VEGF in Cancer 11
- Oncology 43
- Colorectal Cancer Treatments and Studies 11
- Drug Transport and Resistance Mechanisms 10
- Co-authors
- Martin Highley (29 shared papers)Allan T. van Oosterom (28 shared papers)Hans Wildiers (6 shared papers)Bart Landuyt (6 shared papers)Ann Hoeben (2 shared papers)Gert De Boeck (42 shared papers)A.T. van Oosterom (37 shared papers)R. A. A. Maes (24 shared papers)
- Journals
- Anti-Cancer Drugs (7 papers)Journal of Chromatography A (6 papers)Journal of High Resolution Chromatography (5 papers)International Journal of Cancer (4 papers)Annals of Oncology (4 papers)
- Partner nations
- BelgiumNetherlandsUnited Kingdom
In The Last Decade
E. A. de Bruijn
128 papers receiving 4.8k citations
E. A. de Bruijn's Hit Papers
Peers
Comparison fields: 5 of 141
- Toxicology 192
- Oncology 1.4k
- Cancer Research 710
- Genetics 384
- Hematology 402
Countries citing papers authored by E. A. de Bruijn
This map shows the geographic impact of E. A. de Bruijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. A. de Bruijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. A. de Bruijn more than expected).
Fields of papers citing papers by E. A. de Bruijn
This network shows the impact of papers produced by E. A. de Bruijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. A. de Bruijn. The network helps show where E. A. de Bruijn may publish in the future.
Co-authors
The 25 scholars most cited alongside E. A. de Bruijn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 128 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Vascular Endothelial Growth Factor and Angiogenesis Hit paper breakdown → | 2004 | 1491 |
| 2 | 2003 | 252 | |
| 3 | 2008 | 189 | |
| 4 | 1991 | 186 | |
| 5 | 2005 | 159 | |
| 6 | 2000 | 158 | |
| 7 | 2006 | 96 | |
| 8 | 2002 | 92 | |
| 9 | 1999 | 91 | |
| 10 | 2003 | 85 | |
| 11 | 1995 | 83 | |
| 12 | cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. | 1988 | 73 |
| 13 | 1990 | 68 | |
| 14 | 2003 | 59 | |
| 15 | 1996 | 49 | |
| 16 | 1990 | 49 | |
| 17 | 2000 | 48 | |
| 18 | 1996 | 41 | |
| 19 | 2003 | 41 | |
| 20 | 2004 | 40 |
About E. A. de Bruijn
E. A. de Bruijn is a scholar working on Molecular Biology, Oncology, Cancer Research, Pathology and Forensic Medicine and Hematology, having authored 128 papers that have together received 4.9k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (21 papers), Chemotherapy-induced organ toxicity mitigation (13 papers), Angiogenesis and VEGF in Cancer (11 papers), Colorectal Cancer Treatments and Studies (11 papers), Drug Transport and Resistance Mechanisms (10 papers), Bioactive Compounds and Antitumor Agents (9 papers), Cancer, Hypoxia, and Metabolism (9 papers) and Carcinogens and Genotoxicity Assessment (9 papers). The work is most often cited by research in Toxicology (192 citations), Oncology (1.4k citations), Cancer Research (710 citations), Genetics (384 citations) and Hematology (402 citations). E. A. de Bruijn has collaborated with scholars based in Belgium, Netherlands and United Kingdom. Frequent co-authors include Martin Highley, Allan T. van Oosterom, Hans Wildiers, Bart Landuyt, Ann Hoeben, Gert De Boeck, A.T. van Oosterom, R. A. A. Maes, Gunther Guetens and G. Guetens. Their work appears in journals such as Anti-Cancer Drugs, Journal of Chromatography A, Journal of High Resolution Chromatography, International Journal of Cancer and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.